Some biomarkers have been proposed to assess the severity and prognosis of systemic inflammation, infection, and sepsis, such as white blood cell (WBC) count, C-reactive protein (CRP), and procalcitonin (PCT), in critically ill patients.[5,6] Therefore, these biomarkers have been assessed for the early prediction of patients with CRBSI; however, they have shown only limited sensitivity and specificity for the prognosis of CRBSI.[7,8]. The gene discussed is CALCA; the disease is Sepsis.